{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:20:51Z","timestamp":1778509251062,"version":"3.51.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.autrev.2012.09.002","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T12:31:30Z","timestamp":1348057890000},"page":"854-859","source":"Crossref","is-referenced-by-count":36,"title":["Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases"],"prefix":"10.1016","volume":"12","author":[{"given":"Andrea G.","family":"Kattah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 \u201cwhat do B-cells do?\u201d","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0010","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2012.09.002_bb0015","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.autrev.2012.09.002_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2012.09.002_bb0025","first-page":"S14","article-title":"Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab","volume":"56","author":"Genovese","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.autrev.2012.09.002_bb0035","article-title":"Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis","author":"Radice","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0040","first-page":"813","article-title":"Therapy of hepatitis C virus-associated glomerulonephritis: current approaches","volume":"21","author":"Fabrizi","year":"2008","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2011.04.032","article-title":"Epidemiology and management of refractory lupus nephritis","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.autrev.2011.08.002","article-title":"Immune regulatory mechanisms in ANCA-associated vasculitides","volume":"11","author":"Lepse","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.autrev.2011.04.024","article-title":"Refractory vasculitis","volume":"10","author":"Rutgers","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.09.002_bb0065","article-title":"Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis","author":"Sinico","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2012.09.002_bb0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.autrev.2011.11.007","article-title":"B-cell depleting agents for ANCA vasculitides: a new therapeutic approach","volume":"11","author":"G\u00f3mez-Puerta","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0075","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02813430510015269","article-title":"Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response","volume":"34","author":"Omdal","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2008.03.001","article-title":"Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?","volume":"29","author":"Bosch","year":"2008","journal-title":"Trends Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0100","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"164","key":"10.1016\/j.autrev.2012.09.002_bb0115","first-page":"65","article-title":"Long-term efficacy and safety results of the RAVE trial","author":"Specks","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2012.09.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing ANCA-associated vasculitis","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.09.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): A single-center ten-year experience","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0135","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0140","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0145","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","article-title":"B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus","volume":"52","author":"Marks","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2012.09.002_bb0150","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2012.09.002_bb0160","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2012.09.002_bb0165","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2012.09.002_bb0170","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2012.09.002_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0180","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy","volume":"26","author":"Roccatello","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0185","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0190","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0195","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0200","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2011.04.033","article-title":"A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection","volume":"10","author":"Visentini","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2012.09.002_bb0205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00004836-200605000-00018","article-title":"Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab","volume":"40","author":"Pekow","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0210","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/01.tp.0000183749.79424.b4","article-title":"Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients","volume":"80","author":"Basse","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","article-title":"Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature","volume":"11","author":"Ferri","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0220","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0225","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1093\/ndt\/gfl266","article-title":"Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft","volume":"21","author":"Bestard","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0230","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MCG.0b013e3180f60b7a","article-title":"Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis","volume":"42","author":"Evans","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0235","first-page":"27","article-title":"Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia","volume":"66","author":"Korte","year":"2008","journal-title":"Neth J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.09.002_bb0240","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S1590-8658(07)80026-0","article-title":"Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report","volume":"39","author":"Massari","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.09.002_bb0245","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1590-8658(07)80025-9","article-title":"Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab","volume":"39","author":"Petrarca","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0250","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00415-009-5072-z","article-title":"Rituximab in cryoglobulinemic peripheral neuropathy","volume":"256","author":"Cavallo","year":"2009","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2009.10.006","article-title":"Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab","volume":"47","author":"Uppal","year":"2010","journal-title":"J Clin Virol"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0260","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1182\/blood-2007-11-122713","article-title":"Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis","volume":"111","author":"Saadoun","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0265","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/ard.2007.084939","article-title":"Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy","volume":"67","author":"Quartuccio","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0270","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0275","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1002\/art.25000","article-title":"Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis","volume":"60","author":"Sene","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0280","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.09.002_bb0285","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S1590-8658(07)80023-5","article-title":"B-cell depletion in the treatment of mixed cryoglobulinemia","volume":"39","author":"Sansonno","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0290","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-007-8019-0","article-title":"Rituximab as a therapeutic tool in severe mixed cryoglobulinemia","volume":"34","author":"Roccatello","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0305","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1523-1755.2002.00125.x","article-title":"Membranous nephropathy: quo vadis?","volume":"61","author":"Cattran","year":"2002","journal-title":"Kidney Int"},{"issue":"9337","key":"10.1016\/j.autrev.2012.09.002_bb0310","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0315","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0320","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2012.09.002_bb0325","unstructured":"Ruggenenti P, Cravedi P, Narasa M, Ruggiero B, Chianca A, Remuzzi G, Effects of Rituximab in 100 consecutive patients with idiopathic membranous nephropathy and nephrotic syndrome despite RAS inhibition. J Am Soc Nephrol in press."},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0330","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"26","key":"10.1016\/j.autrev.2012.09.002_bb0335","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0340","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"21","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.autrev.2012.09.002_bb0345","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteomics"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2012.09.002_bb0350","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/prca.201000079","article-title":"In vivo characterization of renal auto-antigens involved in human auto-immune diseases: the case of membranous glomerulonephritis","volume":"5","author":"Murtas","year":"2011","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.autrev.2012.09.002_bb0355","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.02170312","article-title":"Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy","author":"Murtas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0360","first-page":"79","article-title":"Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy","volume":"48","author":"Reichert","year":"1997","journal-title":"Clin Nephrol"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0365","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/ndt\/17.11.1890","article-title":"Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis","volume":"17","author":"Bazzi","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0370","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1681\/ASN.2004040287","article-title":"Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study","volume":"16","author":"Branten","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0375","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/ndt\/gfn007","article-title":"Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0380","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/ajkd.2001.26080","article-title":"Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy","volume":"38","author":"Bazzi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2012.09.002_bb0385","unstructured":"Irazabal MV, Eirin A, Lieske J, Beck LH, Borlad TM, Dillon JJ, et al., Low and high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant in press."},{"issue":"7880","key":"10.1016\/j.autrev.2012.09.002_bb0390","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0395","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/00007890-199410000-00018","article-title":"Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment?","volume":"58","author":"Ali","year":"1994","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0400","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0405","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"18","key":"10.1016\/j.autrev.2012.09.002_bb0410","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMc055495","article-title":"Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment","volume":"354","author":"Pescovitz","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2012.09.002_bb0415","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","article-title":"Rituximab therapy for steroid-dependent minimal change nephrotic syndrome","volume":"21","author":"Gilbert","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2012.09.002_bb0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","article-title":"Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0425","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2012.09.002_bb0430","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0435","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","article-title":"Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations","volume":"49","author":"Fran\u00e7ois","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.autrev.2012.09.002_bb0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CNP72069","article-title":"Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome","volume":"72","author":"Sawara","year":"2009","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5414\/CN107092","article-title":"Rituximab in adult patients with immunosuppressive-dependent minimal change disease","volume":"76","author":"Hoxha","year":"2011","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0450","doi-asserted-by":"crossref","first-page":"c79","DOI":"10.1159\/000335142","article-title":"Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature","volume":"120","author":"Kisner","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"8","key":"10.1016\/j.autrev.2012.09.002_bb0455","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.autrev.2012.09.002_bb0460","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2169\/internalmedicine.51.6854","article-title":"Rituximab treatment for adult patients with focal segmental glomerulosclerosis","volume":"51","author":"Ochi","year":"2012","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2012.09.002_bb0465","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1399-3046.2008.00967.x","article-title":"Rituximab for post-transplant recurrences of FSGS","volume":"13","author":"Bayrakci","year":"2009","journal-title":"Pediatr Transplant"},{"issue":"Suppl. 22","key":"10.1016\/j.autrev.2012.09.002_bb0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1399-0012.2010.01279.x","article-title":"Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient","volume":"24","author":"Sakai","year":"2010","journal-title":"Clin Transplant"},{"issue":"12","key":"10.1016\/j.autrev.2012.09.002_bb0475","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2215\/CJN.06720810","article-title":"Posttransplant recurrence of primary glomerulonephritis","volume":"5","author":"Ponticelli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"85","key":"10.1016\/j.autrev.2012.09.002_bb0480","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T12:28:34Z","timestamp":1542716914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1568997212002121"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.09.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}